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Fatal Hepatotoxicity Induced by Hydralazine or
Labetalol
Janice L. Stumpf, Pharm.D.
Antihypertensive agents have been associated with adverse reactions that, if
unrecognized by health practitioners, may have devastating consequences. The
pattern of hepatotoxicity observed during therapy with the vasodilator
hydralazine is highly variable, often making its diagnosis difficult. Serious
hepatic injury induced by the a- and B-adrenergic receptor antagonist labetalol
has only recently been reported and therefore, many clinicians may be unaware
of this adverse effect. Familiarity with the clinical features and course of
hydralazine- and labetalol-induced hepatic injury is necessary to ensure prompt
recognition and discontinuation of the agent.
(Pharmacotherapy 1991 ;11(5):415-418)
In general, the risk of life-threatening adverse
effects posed by antihypertensive agents is
minimal relative to the known complications of
long-term uncontrolled hypertension.' Yet,
antihypertensive agents have been associated
with adverse reactions that can have devastating
consequences if they are not recognized. The
pattern of hepatotoxicity observed during therapy
with the vasodilator hydralazine is highly variable,
making its definitive diagnosis difficult." Serious
hepatic injury induced by the a- and B-adrenergic
receptor antagonist labetalol has only recently
been reported ,3, 4 and therefore, many clinicians
may be unaware of this complicaton.
Case Report
A 73-year-old man with a history of
hypertension, gout, and hyperlipidemia had
controlled his blood pressure well for many years
with reserpine and furosemide. In November
1987, blood pressures were elevated and
hydralazine was initiated. Control remained
suboptimal, and enalapril was substituted for the
reserpine. In January 1988 enalapril was
discontinued and labetalol was prescribed. Two
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months later the patient first related complaints of
anorexia and dark urine of 3 days' duration.
Jaundice and hepatomegaly were noted on
examination. Results of liver function tests were
markedly elevated (Table 1), although they had
been normal 13 months previously. The patient
had no history of fever, chills, alcohol or
intravenous drug abuse, prior liver disease, recent
travel, or blood transfusions. Medications at the
time consisted of labetalol 200 mg twice daily,
hydralazine 50 mg 4 times daily, furosemide 20 mg
once daily, gemfibrozil 300 mg twice daily, and
probenecid 500 mg once daily, all taken by mouth.
On March 23, 1988, the patient came to a local
emergency room with grade IV encephalopathy.
All medications were discontinued, and hydration,
vitamin K, and lactulose were initiated. Laboratory
values indicated severe hepatocellular damage.
The patient was transferred to University
Hospital on the following day for further evaluation
of his acute liver failure. Ultrasonography revealed
no focal lesions or evidence of obstruction.
Antinuclear antibody, hepatitis A IgM antibody,
hepatitis B surface antigen, and hepatitis B core
and surface antibodies were negative. Liver
function continued to deteriorate, and renal failure
developed over the next 5 days. The patient
remained encephalopathic and died on March 29,
1988, 2 weeks after the onset of symptoms.
Liver biopsy performed at autopsy showed
broad stretches of bridging and multilobular
collapse containing pigmented macrophages. The
remaining hepatic parenchyma appeared severely
cholestatic with regenerative changes. In addition,
there were scattered necrotic liver cells and slight
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Table 1. Results of Liver Function Tests"
Lactic
Aspartate Alanine Alkaline Acid
Aminotransferase Aminotransferase Phosphatase Dehydrogenase Bilirubin
Date (lUlL) (lUlL) (lUlL) (lUlL) (mg/dl)
Albumin
(g/dl)
Prothrombin
Time
(sec)
24.3
25.73.5
213/87 21 18 134 136
3/18/88 4230 4590 346 1680
3/23/88 4400 3510 774 26.0
3/24/88 1748 2517 326 441 26.1
3/25/88 1560 156 356 452 32.0
3/26/88 1120 2165 323 469 34.5 3.5
3/27/88 675 2145 296 357 30.0 2.4
3/28/88 329 970 278 376 34.0 2.8 20.0
3/29/88 251 780 278 483 38.0 2.9 20.9
"Normal ranges: aspartate aminotransferase 2-35 lUlL; alanine aminotransferase 0-45 lUlL; alkaline phosphatase 30-130 lUlL; lactic
acid dehydrogenase 60-200 lUlL; bilirubin 0.1-0.9 mg/dl; albumin 3.5-4.9 g/dl; prothrombin time 10-13 sec.
sinusoidal lymphocytosis. The process appeared
to be 2-3 weeks old, but a specific etiology could
not be established. Postmortem examination
revealed a liver of normal size (1000 g) with
numerous punctate hemorrhages in the
parenchyma; all vessels were patent. The
gallbladder and biliary tract were normal.
Discussion
Demonstrating a drug to be the cause of an
adverse reaction relies on knowledge of the
agent's safety profile, confirmation of a temporal
relationship between initiation of the agent and
production of symptoms, and exclusion of other
potential etiologies. 2. 5 Ideally, improvement in
symptoms with drug discontinuation and a positive
rechallenge (i.e., the reappearance of
symptomatology after reexposure to the drug) are
elicited. Many times, however, these conditions
are not fully satisfied, and establishing a conclusive
etiology becomes difficult.
The known hepatotoxic potential of labetalol and
hydralazine, as well as the time course of the
reaction, implicate one of these agents as the
cause of the liver failure in this patient." Symptoms
of hepatic injury were first evident 2 and 4 months
after initiation of labetalol and hydralazine,
respectively. All other medications (furosemide,
gemfibrozil, probenecid) had been taken for many
years without ill effects. In usual dosages they are
not usually associated with serious hepatic injury,
although probenecid was implicated in one case of
fatal hepatitis." Angiotensin-converting enzyme
inhibitors are also uncommon causes of liver injury;
however, acute hepatitis induced by enalapril was
described in two patients after 10 days and 7
weeks of therapy." 7 In this patient, enalapril was
discontinued 2 months prior to the onset of clinical
symptoms, which continued to progress, making
that drug an unlikely cause of the reaction.
Clinical and histologic evidence of drug
hepatotoxicity often resembles that produced by
viruses." In this man, hepatitis serologies were
negative, and cytomegalovirus and Epstein-Barr
virus antibody titers did not indicate acute infection.
Due to the lack of specific diagnostic tests, the
possibility of infection with non-A, non-B hepatitis
cannot be excluded definitively, however, other
clinical findings consistent with a viral illness were
not apparent. There was no lymphocytosis; the
patient remained afebrile, and white blood cell
count and differential were within normal limits until
3 days before he died.
The mechanisms of idiosyncratic adverse drug
reactions can be divided into those of an
immunologic (hypersensitivity) origin and those
due to a metabolic abnormality, in which drug or
metabolites accumulate and exert toxicity." Both
hydralazine":" and labetalol": 14 may induce a
lupus-like illness accompanied by detectable
antinuclear antibodies. Liver disease has been
associated with this syndrome in patients treated
with hydralazine. 9• 1o In this patient the negative
antinuclear antibody titer and the absence of
arthralgias, fever, rash, and eosinophilia made an
immune-mediated process unlikely.
Rather, hepatic injury may have resulted from an
idiosyncrasy in drug metabolism. Liver disease
unaccompanied by lupus-like symptoms has
occurred during therapy with hydralazine15-21 and
labetalol.''" The rate of hepatic acetylation, the
major route of biotransformation of hydralazine, is
genetically determined, and the risk of developing
the lupus-like syndrome is directly correlated with
slow acetylator status." The possibility of a similar
relationship between acetylator status and liver
injury has been suggested, however, hydralazine-
induced hepatitis was reported in a rapid
acetylator." In addition, although lupus-like
manifestations were generally absent, some
patients did have fevers, rashes, or eosinophilia,
indicating a more complex pathogenetic
rnechanisrn.l'' 15,21
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The course of the reaction and available studies
support the possibility of hydralazine-induced
hepatitis in this patient. The onset of symptomatic
hydralazine hepatotoxicity varies from early, within
2-14 days of drug initiation," 18 21 to late, after 2
months to 3 years of therapy.1516, 19 Hepatocellular
necrosis and mixed hepatocellular-cholestatic
hepatitis15-20 are most frequently noted, although
isolated cholestatic hepatitis has been observed."
Histologic analyses have revealed various patterns
of injury, including qranulornas." bridging necrosis
with lobular collapse and inflammatory cell
infiltration;" 17,19 and cholsstas!s." 21 Unlike
hydralazine-induced lupus, the reaction develops
at a relatively low dosage of 50-150 mg daily and
is usually reversible after drug withdrawal.
Rechallenge with hydralazine in three patients
resulted in rapid recurrence of symptoms.":"
The potential for labetalol to induce hepatic
dysfunction was recently emphasized by the drug's
manufacturers in a letter to 285,000 physicians
(written communication, Schering Corporation and
Glaxo Inc., June 5, 1989). In addition, the
prescribing information was revised to reflect the
serious nature of these reactions and the
importance of monitoring liver function tests in
patients receiving the drug.23 24 According to data
from clinical trials, approximately 4% of patients
treated with labetalol may have increases in serum
transaminase concentrations in excess of 3 times
the upper limit of normal. 23,24 In 74% of these
patients, the levels decreased with continued
therapy or after drug withdrawal. However, the
manufacturers' recommendations are that labetalol
be discontinued promptly and not restarted if
laboratory or clinical evidence of liver injury is
documented.
The first published report described a 63-year-
old hypertensive woman with fatal hepatic failure
induced by labetalol." Clinical findings consistent
with liver disease were initially noted after 2.5
months of labetalol 100-200 mg/day. A specific
etiology was not identified, but liver function
improved over 4 weeks after the patient
independently discontinued the drug. During a
follow-up visit, labetalol was again prescribed;
symptoms of hepatic disease were apparent 2
months later. After 2 more months of therapy the
drug was discontinued, however, hepatic function
continued to deteriorate and the patient
subsequently died. Hepatocellular necrosis with
extensive multicellular collapse and fibrotic tissue
surrounding scattered regenerating nodules were
observed on postmortem examination of the liver.
Subsequent to this report, the Food and Drug
Administration evaluated all submitted reports of
hepatotoxicity in patients taking labetalol." A
causal relationship between the drug and liver
disease was thereby established in an additional
10 patients, 2 of whom died as a result of the
reaction. Hepatotoxicity was noted after a median
of 60 days (range 21-189 days) of labetalol
therapy with an average daily dose of 285 mg.
Indicators of a hypersensitivity reaction were
uncommon; none of the patients experienced
elevated temperature, but a maculopapular rash
and mild eosinophilia were documented in one
patient each. Histologic data were available in four
patients and were similar to those reported
previously." Varying degrees of hepatocellular
necrosis with cellular infiltrates and, in one patient,
cholestasis were observed.
This hepatic injury parallels that of the current
patient. There was a 2-month interval between
initiation of labetalol and the onset of symptoms,
and the patient exhibited no signs of an allergic
reaction. Features of the histologic studies were
also similar: extensive hepatocellular damage with
multilobular collapse and cellular infiltrates.
As of April 1989, there were 90 reports of
hepatitis and hepatic necrosis, jaundice, and
elevated liver function tests associated with short-
and long-term labetalol therapy (written
communication, Schering Corporation and Glaxo
Inc., June 5, 1989). Nine of these patients,
including the one described here, died.
The mechanism of liver injury associated with
labetalol is unclear; however, as with hydralazine
hepatotoxicity, it is postulated that affected patients
may have altered metabolic capacities." The
clearance of debrisoquin correlates with the activity
of drug oxidation mediated by the cytochrome P-
450 system, an elimination route of the B-
adrenergic receptor antaqonists." Less than 10%
of the population metabolizes debrisoquin poorly,"
which may explain the low frequency of
hepatotoxicity associated with B-blocking agents.
Metoprolol, a B-blocker with metabolism similar to
that of labetalol, was implicated in one case of
hepatotoxicity, however, studies revealed that
patient was an extensive metabolizer of
debrisoquin." Currently, no published data report
the debrisoquin clearance status of patients with
labetalol-induced liver damage.
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